AnaSpec, EGT Group is pleased to announce the release of three
antibodies (two monoclonal and one polyclonal) against FXYD2γa. FXYD2γa
is a regulating subunit of the NA+-K+-ATPase and has been identified as a unique
and specific pancreatic beta cell surface biomarker. In individuals with Type
1 diabetes or in pancreatic sections of streptozotocin-treated Macacus cynomolgus
monkeys, loss of FXYD2γa has been closely correlated with a loss of insulin
positive cells.1
Anti-hFXYD2γa
antibodies are purified antibodies reacting with an 11 amino acid residue peptide
of FXYD2γa. Monoclonal anti-FXYD2γa
antibodies from Clone 4F9G9 show high specificity towards FXYD2γa beta-cell
biomarker while monoclonal anti-FXYD2γa antibodies from Clone 3C1D10 show
high sensitivity towards FXYD2γa beta-cell biomarker. A rabbit polyclonal
anti-hFXYD2γa antibody is also available (see Table 1). These antibodies can be used for beta cell specific targeting
and non-invasive imaging. The use of targeting strategies against the biomarker
(FXYD2γa) allows early identification of beta cell and the follow up of
therapies for diabetes patients.
Table 1. Anti-FXYD2γa antibodies are available as monoclonal or polyclonal.
Feature
| Catalog # |
AB-FXYD2-M1 |
AB-FXYD2-M2 |
AB-FXYD2-P1 |
| Form |
Purified
(PBS; 0.01% thimerosal p/V final) |
Purified
(PBS; 0.01% thimerosal p/V final) |
Purified
(PBS; 0.1% BSA p/V final; 0.01% thimerosal p/V final) |
| Clonality |
monoclonal |
monoclonal |
polyclonal |
| Clone |
4F9G9 |
3C1D10 |
NA |
| Host |
Mouse |
Mouse |
Rabbit |
| Species reactivity |
Human & Primate |
Human & Primate |
Human & Primate |
| Application |
ELISA, WB, IHC |
ELISA, WB, IHC |
ELISA, WB, IHC, FC |
| Suggested working dilution* |
IHC 1:150-200
WB 1:400
ELISA 1:400 |
IHC 1:150-200
WB 1:400
ELISA 1:400 |
IHC 1:333
WB 1:1000
ELISA 1:1000
FC 1: 333 |
*Optimal working dilution should be determined for each specific
assay condition
Results
Monoclonal anti-FXYD2γa antibodies
anti-FXYD2γa
(4F9G9) antibodies show high specificity towards FXYD2γa beta-cell biomarker
anti-FXYD2γa (3C1D10) antibodies show high sensitivity towards FXYD2γa
beta-cell biomarker
| Insulin
 |
Insulin
 |
Analysis
by immunohistochemistry of normal human pancreas paraffin section of
3 μM, magnification 400X
Use of anti-insulin antibody (upper row); anti-FXYD2γa
(3C1D10) (middle row) and anti-glucagon antibody (lower row)
Use of anti-insulin antibody (upper row); anti-FXYD2γa (4F9G9)
(middle row) and anti-glucagon antibody (lower row)
Courtesy of Prof. I. Salmon - Laboratory of Pathology, Erasme Hospital,
Université Libre de Bruxelles, Brussels, Belgium |
| 3C1D10
|
4F9G9
|
| Glucagon
 |
Glucagon
 |
Polyclonal anti-FXYD2γa antibodies
FXYD2γa is specifically present in beta cells in human and macaque
pancreas
| Human FXYD2γa
|
Macacus cynomolgus FXYD2γa
|
FXYD2γa was specifically present in beta cells in human
and macaque (Macacus cynomolgus) pancreas. Consecutive paraffin sections
of human (left column) and macaque (right column) pancreas were analyzed
by immunohistochemistry with polyclonal rabbit anti-FXYD2γa (upper
row), anti-insulin antibody (middle row) and anti-glucagon antibody
(lower row). Magnification 400×
Reference: D. Flamez et al., Diabetologia. 2010 Jul.53(7):1372-83 |
| Human Insulin
|
Macacus cynomolgus Insulin
 |
| Human Glucagon
|
Macacus cynomolgus Glucagon
|
Early presence of FXYD2 in human endocrine pancreas
 |
Early presence of FXYD2 in human endocrine pancreas. Consecutive
paraffin sections of fetal human pancreas (15, 18 and 25 weeks) were
analyzed by immunofluorescence. Green, FXYD2γa; red, insulin; blue,
glucagon; yellow/orange, colocalization of FXYD2γa and insulin. There
was no colocalization of FXYD2γa with glucagon. Magnification 400×
Reference: D. Flamez et al., Diabetologia. 2010 Jul.53(7):1372-83 |
Decreased presence of FXYD2γa correlated with beta cell loss
 |
Decreased presence of FXYD2γa correlated with beta cell
loss in three patients with type 1 diabetes. Consecutive sections of
pancreas from an individual control (Ctrl) and three individual patients
with type 1 diabetes. These patients had different durations of diabetes
(3 years, 25 years and 3 days). The samples were analyzed with polyclonal
anti-FXYD2γa antibody (SPY393) (left column), anti-insulin antibody
(middle column) or anti-glucagon antibody (right column) |
Reference
1.
Flamez, D. et al. Diabetologia. 2010 Jul.53(7):1372-83.
Eurogentec has an exclusive license under patent n° WO2009/101181 A2. Use of this product employs the following patent rights exclusively licensed to Eurogentec S.A. : (a) any claims issuing from the following Patent Applications Serial Nos. 9710674,4, 12/735,731 and 2010-546352 and (b) all patents to be issued pursuant thereto, and all continuations, continuations-in-part, reissues, substitutes, and extensions thereof. The purchase of this product includes a limited, non-transferable immunity from suit under the foregoing patent claims for using only this amount of product for the purchaser's own internal research. No right under any other patent claim and no right to perform commercial services of any kind, including without limitation reporting the results of purchaser's activities for a fee or other commercial consideration, is conveyed expressly, by implication, or by estoppel. This product is for research use only. Diagnostic uses under these patents require a separate license from Eurogentec S.A.
|
